CGEM in the 13F filings
Cullinan Oncology Inc · CUSIP 230031106
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 18 May 2026
- latest of these filings; the earliest 12 May 2026
- Managers listing it
- 19
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 0 listed it in both
- Shares listed
- 6,487,571
- combined, among listed positions
- Reported value
- $92m
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 13 buyers (opened or added shares) and 8 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +3,063,432.
Managers listing CGEM in Q1 2026
19 of 19 holders
Largest increases and reductions, by shares
Increases
- T. Rowe Price Associates Incexisting position · 2,029,719 shares now+1,982,532
- Marshall Wace LLPexisting position · 1,049,581 shares now+635,222
- Point72 Asset Management LPexisting position · 905,376 shares now+545,214
- Citadel Advisors LLCexisting position · 252,778 shares now+142,461
- Invesco Ltdexisting position · 244,150 shares now+113,827
Reductions
- Renaissance Technologies LLCexisting position · 324,111 shares now-307,595
- Jane Street Group LLCexisting position · 22,812 shares now-164,032
- Millennium Management LLCexisting position · 346,582 shares now-15,913
- Wellington Management Group LLPexisting position · 149,626 shares now-10,125
New positions and exits
New (2)
Exited (4)
- Squarepoint Ops LLCwas $785k
- ExodusPoint Capital Management LPwas $316k
- Schonfeld Strategic Advisors LLCwas $172k
- D. E. Shaw & Co.was $149k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2021 | 3 | $100m | n.a. | n.a. |
| Q2 2021 | 2 | $61m | n.a. | n.a. |
| Q3 2021 | 2 | $51m | n.a. | n.a. |
| Q4 2021 | 2 | $30m | n.a. | n.a. |
| Q1 2022 | 2 | $21m | n.a. | n.a. |
| Q2 2022 | 2 | $30m | n.a. | n.a. |
| Q3 2022 | 1 | $5.5m | n.a. | n.a. |
| Q4 2022 | 1 | $2.1m | n.a. | n.a. |
| Q1 2023 | 1 | $108k | n.a. | n.a. |
| Q2 2023 | 1 | $2.4m | n.a. | n.a. |
| Q3 2023 | 1 | $2.0m | n.a. | n.a. |
| Q4 2023 | 1 | $2.3m | 0 | 0 |
| Q2 2024 | 2 | $44m | 2 | 0 |
| Q3 2024 | 1 | $26m | 1 | 0 |
| Q1 2026 | 1 | $1.5m | 13 | 8 |
| Q2 2026 | 1 | $3.5m | 13 | 9 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
CGEM and GILD →CGEM and AMGN →CGEM and ARGX →Choose a stock to compare with CGEM →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own CGEM, latest filings →Back to the 13F Explorer →